Short Stature and Pubertal Delay in Male Adolescents With Cystic Fibrosis: Androgen Treatment

Christopher Landon, Ronald (Ron) Rosenfeld

Research output: Contribution to journalArticle

63 Citations (Scopus)

Abstract

We evaluated the growth rate and pubertal status of 54 adolescent and young adult men with cystic fibrosis and assessed the efficacy of short-term androgen therapy in promoting growth and pubertal development. Thirty-nine percent were below the fifth percentile in height and 8/28 between the ages of 14 and 18 had delays in pubertal development. Five male adolescents aged 13 years 8 months to 18 years 3 months were treated with testosterone and their conditions were prospectively evaluated. Growth rate increased from an entry mean of 2.2 cm/yr to 7.2 cm/yr (3 to 10 cm/yr). We conclude that a brief course of testosterone appears to be a safe, effective means of improving growth rate in male adolescents with cystic fibrosis with delay of puberty.

Original languageEnglish (US)
Pages (from-to)388-391
Number of pages4
JournalAmerican Journal of Diseases of Children
Volume138
Issue number4
DOIs
StatePublished - 1984
Externally publishedYes

Fingerprint

Cystic Fibrosis
Androgens
Testosterone
Growth
Puberty
Growth and Development
Young Adult
Therapeutics

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

Short Stature and Pubertal Delay in Male Adolescents With Cystic Fibrosis : Androgen Treatment. / Landon, Christopher; Rosenfeld, Ronald (Ron).

In: American Journal of Diseases of Children, Vol. 138, No. 4, 1984, p. 388-391.

Research output: Contribution to journalArticle

Landon, Christopher ; Rosenfeld, Ronald (Ron). / Short Stature and Pubertal Delay in Male Adolescents With Cystic Fibrosis : Androgen Treatment. In: American Journal of Diseases of Children. 1984 ; Vol. 138, No. 4. pp. 388-391.
@article{4192fa00f43a400593e8f7b8a04198fa,
title = "Short Stature and Pubertal Delay in Male Adolescents With Cystic Fibrosis: Androgen Treatment",
abstract = "We evaluated the growth rate and pubertal status of 54 adolescent and young adult men with cystic fibrosis and assessed the efficacy of short-term androgen therapy in promoting growth and pubertal development. Thirty-nine percent were below the fifth percentile in height and 8/28 between the ages of 14 and 18 had delays in pubertal development. Five male adolescents aged 13 years 8 months to 18 years 3 months were treated with testosterone and their conditions were prospectively evaluated. Growth rate increased from an entry mean of 2.2 cm/yr to 7.2 cm/yr (3 to 10 cm/yr). We conclude that a brief course of testosterone appears to be a safe, effective means of improving growth rate in male adolescents with cystic fibrosis with delay of puberty.",
author = "Christopher Landon and Rosenfeld, {Ronald (Ron)}",
year = "1984",
doi = "10.1001/archpedi.1984.02140420054017",
language = "English (US)",
volume = "138",
pages = "388--391",
journal = "JAMA Pediatrics",
issn = "2168-6203",
publisher = "American Medical Association",
number = "4",

}

TY - JOUR

T1 - Short Stature and Pubertal Delay in Male Adolescents With Cystic Fibrosis

T2 - Androgen Treatment

AU - Landon, Christopher

AU - Rosenfeld, Ronald (Ron)

PY - 1984

Y1 - 1984

N2 - We evaluated the growth rate and pubertal status of 54 adolescent and young adult men with cystic fibrosis and assessed the efficacy of short-term androgen therapy in promoting growth and pubertal development. Thirty-nine percent were below the fifth percentile in height and 8/28 between the ages of 14 and 18 had delays in pubertal development. Five male adolescents aged 13 years 8 months to 18 years 3 months were treated with testosterone and their conditions were prospectively evaluated. Growth rate increased from an entry mean of 2.2 cm/yr to 7.2 cm/yr (3 to 10 cm/yr). We conclude that a brief course of testosterone appears to be a safe, effective means of improving growth rate in male adolescents with cystic fibrosis with delay of puberty.

AB - We evaluated the growth rate and pubertal status of 54 adolescent and young adult men with cystic fibrosis and assessed the efficacy of short-term androgen therapy in promoting growth and pubertal development. Thirty-nine percent were below the fifth percentile in height and 8/28 between the ages of 14 and 18 had delays in pubertal development. Five male adolescents aged 13 years 8 months to 18 years 3 months were treated with testosterone and their conditions were prospectively evaluated. Growth rate increased from an entry mean of 2.2 cm/yr to 7.2 cm/yr (3 to 10 cm/yr). We conclude that a brief course of testosterone appears to be a safe, effective means of improving growth rate in male adolescents with cystic fibrosis with delay of puberty.

UR - http://www.scopus.com/inward/record.url?scp=0021343594&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021343594&partnerID=8YFLogxK

U2 - 10.1001/archpedi.1984.02140420054017

DO - 10.1001/archpedi.1984.02140420054017

M3 - Article

C2 - 6702792

AN - SCOPUS:0021343594

VL - 138

SP - 388

EP - 391

JO - JAMA Pediatrics

JF - JAMA Pediatrics

SN - 2168-6203

IS - 4

ER -